Aveo Drug Patent Portfolio
Aveo owns 1 orange book drug protected by 3 US patents Given below is the list of Aveo's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11504365 | Use of tivozanib to treat subjects with refractory cancer | 05 Nov, 2039 | Active |
| US7166722 | N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-n′-(5-methyl-3-isoxazolyl)urea salt in crystalline form | 16 Nov, 2028 | Active |
| US6821987 | Quinoline derivatives and quinazoline derivatives having azolyl group | 26 Apr, 2025 | Expired |
Latest Legal Activities on Aveo's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Aveo.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Patent Term Extension Certificate | 04 Mar, 2025 | US7166722 |
| Withdrawal of Application for PTE | 04 Mar, 2025 | US6821987 |
| Election in Response to Notice of Final Determination | 27 Feb, 2025 | US7166722 |
| Election in Response to Notice of Final Determination | 27 Feb, 2025 | US6821987 |
| Notice of Final Determination -Election Required | 31 Jan, 2025 | US7166722 |
| Notice of Final Determination -Election Required | 31 Jan, 2025 | US6821987 |
| FDA Final Eligibility Letter | 13 Jan, 2025 | US7166722 |
| FDA Final Eligibility Letter | 13 Jan, 2025 | US6821987 |
| Interim Patent Term Extension Granted | 13 Nov, 2024 | US7166722 |
| Interim Patent Term Extension Request Under 35 USC 156(e)(2) | 14 Aug, 2024 | US7166722 |
|
Interim Patent Term Extension Granted
Critical
| 18 Mar, 2024 | US6821987 |
| transaction for FDA Determination of Regulatory Review Period | 28 Dec, 2023 | US6821987 |
| transaction for FDA Determination of Regulatory Review Period | 28 Dec, 2023 | US7166722 |
| transaction for FDA Determination of Regulatory Review Period | 08 Dec, 2023 | US6821987 |
| transaction for FDA Determination of Regulatory Review Period | 08 Dec, 2023 | US7166722 |
Aveo's Family Patents
Aveo Drug List
Given below is the complete list of Aveo's drugs and the patents protecting them.
1. Fotivda
Fotivda is protected by 3 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11504365 | Use of tivozanib to treat subjects with refractory cancer |
05 Nov, 2039
(13 years from now)
| Active |
| US7166722 | N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-n′-(5-methyl-3-isoxazolyl)urea salt in crystalline form |
16 Nov, 2028
(2 years from now)
| Active |
| US6821987 | Quinoline derivatives and quinazoline derivatives having azolyl group |
26 Apr, 2025
(10 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Fotivda's drug page